Tildrakizumab-Asmn

Last Updated: 04/28/2026

Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
2 clinical trials found

    A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

    A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

    Enrollment Status: Recruiting
    Publish Date: January 27, 2026

    Summary: This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale...

    A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

    A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.

    Who is this study for: Patients with moderate-to-severe plaque psoriasis
    Enrollment Status: Recruiting
    Publish Date: April 15, 2020
    Intervention Type: Drug
    Study Drug: Ilumya Injectable Product
    Study Phase: Phase 4

    Summary: Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

    Showing 1-2 of 2

    Last Updated: 04/28/2026